CNBC January 7, 2025
Key Points
– Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca’s Tagrisso in a clinical trial.
– J&J is trying to supplant AstraZeneca’s blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations.
– It remains to be seen how many doctors will adopt the treatment.
Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer.
J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and...
Today's Sponsors
Today's Sponsor